Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$5.23M Buy
80,700
+45,200
+127% +$2.86M ﹤0.01% 1980
2014
Q2
$2.21M Sell
35,500
-84,500
-70% -$5.04M ﹤0.01% 2775
2014
Q1
$7.06M Sell
120,000
-60,500
-34% -$3.38M 0.01% 1530
2013
Q4
$9.21M Sell
180,500
-109,000
-38% -$5.46M 0.01% 1315
2013
Q3
$14.6M Buy
289,500
+162,400
+128% +$8.5M 0.01% 882
2013
Q2
$6.24M Buy
+127,100
New +$6.92M 0.01% 1419

Other funds holding LLY

UBS's LLY Position: Q3 2014 in Review

UBS increased its Eli Lilly (LLY) stake by 5.7% in Q3 2014, buying an estimated $2.43M and bringing the position to 707,528 shares worth $45.9M. The position accounts for 0.03% of the portfolio, ranked #545.

UBS first reported a position in LLY in Q2 2013 and has held it in 6 quarters since. The position peaked at $46M in Q3 2013. 1,041 funds tracked by Wall St. Rank hold LLY as of Q3 2014.

  • UBS held 707,528 shares of Eli Lilly worth $45.9M as of Q3 2014.
  • UBS bought 38,330 Eli Lilly shares in Q3 2014, an estimated $2.43M.
  • Eli Lilly made up 0.03% of UBS's portfolio in Q3 2014, its #545 holding.
  • UBS first reported a position in Eli Lilly in Q2 2013 and has held it in 6 quarters since.
  • UBS's Eli Lilly position peaked at $46M in Q3 2013.
  • 1,041 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.